Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Single Intravenous (IV) TAK-954

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. All participants: Male and female participants (non-childbearing potential) who are aged 18 to 75 years, inclusive, with a body mass index (BMI) between 18 to 35 kilogram per square meter (kg/m\^2).~2. Group A: As much as possible, the healthy participants with normal renal function (creatinine clearance \[CLcr\] greater than or equal to \[\>=\] 90 milliliter per minute \[mL/min\]) should be comparable to participants with renal impairment with respect to median age and weight (approximately 50 percent \[%\] of healthy participants on each side of the median age and weight of currently enrolled renally-impaired participants grouped together), sex, and race. This will be decided by the investigators in discussion with Takeda.~3. Groups B to E: Participants who have stable RI, defined as no clinically significant change in disease status, as documented by the participant's most recent CLcr assessment; serum creatinine must not vary more than approximately 30% from Screening to Day -1 to confirm stable disease. Participants should also be in good health commensurate with their renal status.~   * Group B: Participants with mild RI (CLcr 60 to less than \[\<\] 90 mL/min).~  * Group C: Participants with moderate RI (CLcr 30 to \<60 mL/min).~  * Group D: Participants with severe RI or ESRD but not requiring dialysis (CLcr \<30 mL/min).~  * Group E: Participants with ESRD requiring dialysis (\<15 mL/min requiring hemodialysis at least 3 times/week, and having been on the same dialysis treatment regimen for at least 1 month before trial entry).~4. Participants should be on a stable drug regimen defined as not starting a new drug or changing dosage within 7 days or 5 half-lives (whichever is longer) before dosing with TAK-954.~Exclusion Criteria:~1. All participants:~   * Are renal allograft recipients within 1 year of screening.~  * Have a history of gastrointestinal (GI) motility disorder or intestinal obstruction.~  * Have urinary incontinence without catheterization.~2. Group A: Participants who, in the discretion of the investigator, have a history of clinically significant endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases will be excluded from the trial.~3. Groups B to E:~   * Receive dialysis other than intermittent dialysis (except Group E).~  * Have renal disease secondary to hepatic disease (hepatorenal syndrome).~  * At the discretion of the investigators, have any significant hepatic, cardiac, or pulmonary disease or participants who are clinically nephrotic.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Group A TAK-954 0.2 mg: Healthy Participants (Type: EXPERIMENTAL): Participants with normal renal function receive TAK-954 0.2 milligram (mg), infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
- Group B TAK-954 0.2 mg: Mild Renal Impairment (Type: EXPERIMENTAL): Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
- Group C TAK-954 0.2 mg: Moderate Renal Impairment (Type: EXPERIMENTAL): Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
- Group D TAK-954 0.2 mg: Severe Renal Impairment (Type: EXPERIMENTAL): Participants without hemodialysis or End-stage Renal Disease (ESRD) receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
- Group E TAK-954 0.2 mg: End-stage Renal Disease (ESRD) (Type: EXPERIMENTAL): Participants with hemodialysis receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period followed by a minimum 13-day washout period, further followed by TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period.

Based on this trial design, predict the completion outcome and termination type (if applicable).